Linked Life Data

16080681

Source:http://linkedlifedata.com/resource/pubmed/id/16080681

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16080681rdf:typepubmed:Citationlld:pubmed
pubmed-article:16080681lifeskim:mentionsumls-concept:C0376613lld:lifeskim
pubmed-article:16080681lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:16080681lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:16080681lifeskim:mentionsumls-concept:C1552514lld:lifeskim
pubmed-article:16080681lifeskim:mentionsumls-concept:C0336809lld:lifeskim
pubmed-article:16080681pubmed:issue4lld:pubmed
pubmed-article:16080681pubmed:dateCreated2005-8-5lld:pubmed
pubmed-article:16080681pubmed:abstractTextFor many microbial fermentation processes, the inoculum train can have a substantial impact on process performance in terms of productivity, profitability, and process control. In general, it is understood that a well-characterized and flexible inoculum train is essential for future scale-up and implementation of the process in a pilot plant or manufacturing setting. A fermentation process utilizing E. coli DH5 for the production of plasmid DNA carrying the HIV gag gene for use as a vaccine is currently under development in our laboratory. As part of the development effort, we evaluated inoculum train schemes that incorporate one, two, or three stages. In addition, we investigated the effect of inoculum viable-cell concentrations, either thawed or actively growing, over a wide range (from 2.5 x 10(4) to 1.0 x 10(8) viable cells/mL or approximately 0.001% to 4% of final working volume). The various inoculum trains were evaluated in terms of final plasmid yield, process time, reproducibility, robustness, and feasibility at large scale. The results of these studies show that final plasmid yield remained in the desired range, despite the number of stages or inoculation viable-cell concentrations comprising the inoculum train. On the basis of these observations and because it established a large database, the first part of these investigations supports an exceptional flexibility in the design of scalable inoculum trains for this DNA vaccine process. This work also highlighted that a slightly higher level of process reproducibility, as measured by the time for the culture to reach mid-exponential growth, was observed when using actively growing versus frozen cells. It also demonstrated the existence of a viable-cell concentration threshold for the one-stage process, since we observed that inoculation of the production stage with very low amounts of viable cells from a frozen source could lead to increased process sensitivity to external factors such as variation in the quality of the raw materials used in the medium formulation. However, our analysis indicates that, despite this slight disadvantage, a one-stage inoculum train was a viable option in many situations, especially if the inoculation viable-cell concentration was kept above 4.8 x 10(6) viable cells/mL. Because it leads to a reduction in process steps and eliminates some capital investments (i.e., inoculum fermenter), when feasible a one-stage process configuration will positively impact process economics.lld:pubmed
pubmed-article:16080681pubmed:languageenglld:pubmed
pubmed-article:16080681pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16080681pubmed:citationSubsetIMlld:pubmed
pubmed-article:16080681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16080681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16080681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16080681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16080681pubmed:statusMEDLINElld:pubmed
pubmed-article:16080681pubmed:issn8756-7938lld:pubmed
pubmed-article:16080681pubmed:authorpubmed-author:RobinsonDDlld:pubmed
pubmed-article:16080681pubmed:authorpubmed-author:ChartrainMMlld:pubmed
pubmed-article:16080681pubmed:authorpubmed-author:OkonkowskiJJlld:pubmed
pubmed-article:16080681pubmed:authorpubmed-author:Kizer-Bentley...lld:pubmed
pubmed-article:16080681pubmed:authorpubmed-author:ListnerKKlld:pubmed
pubmed-article:16080681pubmed:issnTypePrintlld:pubmed
pubmed-article:16080681pubmed:volume21lld:pubmed
pubmed-article:16080681pubmed:ownerNLMlld:pubmed
pubmed-article:16080681pubmed:authorsCompleteYlld:pubmed
pubmed-article:16080681pubmed:pagination1038-47lld:pubmed
pubmed-article:16080681pubmed:dateRevised2006-5-1lld:pubmed
pubmed-article:16080681pubmed:meshHeadingpubmed-meshheading:16080681...lld:pubmed
pubmed-article:16080681pubmed:meshHeadingpubmed-meshheading:16080681...lld:pubmed
pubmed-article:16080681pubmed:meshHeadingpubmed-meshheading:16080681...lld:pubmed
pubmed-article:16080681pubmed:meshHeadingpubmed-meshheading:16080681...lld:pubmed
pubmed-article:16080681pubmed:meshHeadingpubmed-meshheading:16080681...lld:pubmed
pubmed-article:16080681pubmed:meshHeadingpubmed-meshheading:16080681...lld:pubmed
pubmed-article:16080681pubmed:meshHeadingpubmed-meshheading:16080681...lld:pubmed
pubmed-article:16080681pubmed:meshHeadingpubmed-meshheading:16080681...lld:pubmed
pubmed-article:16080681pubmed:meshHeadingpubmed-meshheading:16080681...lld:pubmed
pubmed-article:16080681pubmed:articleTitleDevelopment of a robust, versatile, and scalable inoculum train for the production of a DNA vaccine.lld:pubmed
pubmed-article:16080681pubmed:affiliationBioprocess R&D, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA.lld:pubmed
pubmed-article:16080681pubmed:publicationTypeJournal Articlelld:pubmed